Search results for "Cushing syndrome"

showing 8 items of 18 documents

Very Low-Calorie Ketogenic Diet: A Potential Application in the Treatment of Hypercortisolism Comorbidities

2022

A very low-calorie ketogenic diet (VLCKD) is characterized by low daily caloric intake (less than 800 kcal/day), low carbohydrate intake (<50 g/day) and normoproteic (1–1.5 g of protein/kg of ideal body weight) contents. It induces a significant weight loss and an improvement in lipid parameters, blood pressure, glycaemic indices and insulin sensitivity in patients with obesity and type 2 diabetes mellitus. Cushing’s syndrome (CS) is characterized by an endogenous or exogenous excess of glucocorticoids and shows many comorbidities including cardiovascular disease, obesity, type 2 diabetes mellitus and lipid disorders. The aim of this speculative review is to provide an overview on nutrit…

Nutrition and DieteticsDiabetes Mellitus Type 2Cushing’s syndromediabetes mellituHumansglucocorticoidObesitycortisolDiet KetogenicCushing SyndromeLipidsFood Scienceobesity.
researchProduct

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

2014

Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endoge…

Oncologymedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismOsteoporosisHypercortisolismAdrenal incidentaloma; Cushing's disease; Glucocorticoids; Osteoporosis; Bone Density Conservation Agents; Cushing Syndrome; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Risk FactorsEndogenyDiseaseadrenal incidentalomaBone remodelingRisk FactorsInternal medicinemedicineHumansCushing SyndromeBone Density Conservation Agentsglucocorticoidsbusiness.industrycushing's diseaseCushing's diseasemedicine.diseaseosteoporosisRheumatologyglucocorticoids; osteoporosis; cushing's disease; adrenal incidentalomaEndocrinologyAdrenal incidentaloma; CUSHING'S DISEASE; Glucocorticoids; OsteoporosisbusinessGlucocorticoidOsteoporotic Fracturesmedicine.drug
researchProduct

A decision dilemma: Cushing syndrome during pregnancy.

2014

The rare presentation of Cushing syndrome during pregnancy prevents the use of established guidelines for management. A three-step dilemma challenges clinicians making this diagnosis: surveillance,...

Pediatricsmedicine.medical_specialtyPregnancybusiness.industryObstetrics and Gynecologymedicine.diseaseDilemmaPregnancy ComplicationsCushing syndromeYoung AdultPregnancymedicineHumansFemalePresentation (obstetrics)businessCushing SyndromeJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
researchProduct

Selektive Blutentnahme aus dem Sinus petrosus inferior: Vergleich von CRF- und TRH-Stimulation

1993

In 10 patients with hypophyseal Cushing microadenomas, selective bilateral sampling from the inferior petrosal sinuses was performed and the effect of stimulation by iv TRH and CRF was compared. On the side of the microadenoma. ACTH concentration rose from 650 +/- 242 pg/ml to 2712 +/- 843 pg/ml following injection of CRF and 2025 +/- 242 pg/ml after TRH. Contralateral values were 165 +/- 79 pg/ml, 490 +/- 200 pg/ml and 165 +/- 72 pg/ml respectively. Prolactin concentration on the side of the adenoma was 98 +/- 49 ng/ml before stimulation, 236 +/- 62 ng/ml after CRF and 747 +/- 168 ng/ml after TRH. Contralateral concentration was 22 +/- 10 ng/ml, 64 +/- 19 ng/ml respectively. Sampling local…

Pituitary glandmedicine.medical_specialtyAdenomabusiness.industryInferior petrosal sinusStimulationRadioimmunoassaymedicine.diseaseProlactinCushing syndromemedicine.anatomical_structureEndocrinologyInternal medicinemedicineRadiology Nuclear Medicine and imagingbusinessBlood samplingRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Incidentaloma Surrenalico. Caso di Sindrome di Cushing subclinica.

2004

The authors describe a case of adrenal incidentaloma that was the cause of subclinical Cushing's syndrome and take the opportunity to weigh up some of the clinical, diagnostic and therapeutic aspects. Besides the particular expression of the symptoms which were difficult to interpret before reaching a diagnosis, the authors describe the diagnostic work-up adopted, aimed at precisely identifying the type of tumour and the surgical procedure implemented laparoscopically, the outstanding validity of which is confirmed compared to traditional adrenalectomy techniques.

adrenal tumorfemaleincidental findingmiddle agedarticlelaparoscopyadrenalectomycase reportCushing syndromemethodologypathologyhuman
researchProduct

Glucocorticoid excess and COVID-19 disease

2020

AbstractThe pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and mortality. Immune system response plays a crucial role in controlling and resolving the viral infection. Exogenous or endogenous glucocorticoid excess is characterized by increased susceptibility to infections, due to impairment of the innate and adaptive immune system. In addition, diabetes, hypertension, obesity and thromboembolism are conditions overrepresented in patients with hypercortisolism. Thus patients with chronic glucocorticoid (GC) excess may be at high risk of developing COVID-19 infection with a sever…

cortisol; cushing’s syndrome; glucocorticoid; immune system; infections; SarsCoV2Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseasemedicine.disease_causeBioinformaticsSarsCoV2InfectionsArticleCortisolSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineImmune systemEndocrinologyGlucocorticoidSarsCoV2.Diabetes mellitusPandemicMedicineHumans030212 general & internal medicineCushing SyndromeGlucocorticoidsPandemicsCoronavirusbusiness.industrySARS-CoV-2COVID-19medicine.diseaseAcquired immune systemObesityImmune systemCushing’s syndromebusinessInfectionGlucocorticoidmedicine.drugReviews in Endocrine & Metabolic Disorders
researchProduct

Safety of human and ovine corticotropin-releasing hormone.

1986

medicine.medical_specialtyAdolescentbusiness.industryCorticotropin-Releasing HormoneGeneral MedicineCorticotropin-releasing hormoneEndocrinologyInternal medicinemedicineAnimalsHumansFemalebusinessCushing SyndromeLancet (London, England)
researchProduct

Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease

1987

medicine.medical_specialtyHydrocortisoneCorticotropin-Releasing HormoneDepressionbusiness.industryGeneral MedicineCushing's diseasemedicine.diseaseCorticotropin-releasing hormoneEndocrinologyAdrenocorticotropic HormoneInternal medicinemedicineHumansbusinessCushing SyndromeDepression (differential diagnoses)New England Journal of Medicine
researchProduct